Insulin is critical for the regulation of de novo fatty acid synthesis, which converts glucose to lipid in the liver. However, how insulin signals are transduced into the cell and then regulate lipogenesis remains to be fully understood. Here, we identified CREB/ATF bZIP transcription factor (CREBZF) of the activating transcription factor/cAMP response element-binding protein (ATF/ CREB) gene family as a key regulator for lipogenesis through insulin-Akt signaling. Insulin-induced gene 2a (Insig-2a) decreases during refeeding, allowing sterol regulatory element binding protein 1c to be processed to promote lipogenesis; but the mechanism of reduction is unknown. We show that Insig-2a inhibition is mediated by insulin-induced CREBZF. CREBZF directly inhibits transcription of Insig-2a through association with activating transcription factor 4. Liver-specific knockout of CREBZF causes an induction of Insig-2a and Insig-1 and resulted in repressed lipogenic program in the liver of mice during refeeding or upon treatment with streptozotocin and insulin. Moreover, hepatic CREBZF deficiency attenuates hepatic steatosis in high-fat, high-sucrose diet-fed mice. Importantly, expression levels of CREBZF are increased in livers of diet-induced insulin resistance or genetically obese ob/ob mice and humans with hepatic steatosis, which may underscore the potential role of CREBZF in the development of sustained lipogenesis in the liver under selective insulin resistance conditions. Conclusion: These findings uncover an unexpected mechanism that couples changes in extracellular hormonal signals to hepatic lipid homeostasis; disrupting CREBZF function may have the therapeutic potential for treating fatty liver disease and insulin resistance. (HEPATOLOGY 2018; 68:1361-1375).
I
ncreased de novo lipogenesis and excessive triglyceride accumulation in the liver caused by metabolic alterations are hallmarks of nonalcoholic fatty liver disease (NAFLD) pathology and are strongly associated with obesity, insulin resistance, and type 2 diabetes.
(1) The liver is a key organ for the control of lipid metabolism under nutrient deprivation and availability. Insulin stimulates de novo lipid synthesis through the activation of sterol regulatory element binding protein (SREBP) isoforms in the liver to promote lipogenic gene expression and fatty acid synthesis. (2) (3) (4) SREBPs are escorted from the endoplasmic reticulum (ER) to the Golgi apparatus by SREBP cleavage-activating protein (SCAP) upon activation, Abbreviations: ACC1, acetyl-coenzyme A carboxylase 1; Ad-sh, adenovirus encoding shRNA; Alb-Cre, albumin-cyclization recombination; ATF, activating transcription factor; bZIP, basic region-leucine zipper; C/EBP, CCAAT/enhancer binding protein; CREB, cAMP response element-binding protein; CREBZF, bZIP transcription factor of the ATF/CREB gene family; ER, endoplasmic reticulum; FAS, fatty acid synthase; GFP, green fluorescent protein; GST, glutathione S-transferase; HFHS, high-fat, high-sucrose; IgG, immunoglobulin G; Insig, insulin-induced gene; LKO, liverspecific knockout; LXR, liver X receptor; PI3K, phosphoinositide 3-kinase; SCAP, SREBP cleavage-activating protein; shRNA, short hairpin RNA; si, small interfering; SREBP, sterol regulatory element binding protein; STZ, streptozotocin; WT, wild type.
where the NH 2 -terminal domain of SREBP is proteolytically released, is translocated to the nucleus, and then activates transcription by binding to sterol response elements (SREs) in the promoter regions of lipogenic target genes. (4) Increased lipogenesis and excessive triglyceride accumulation in the liver caused by metabolic alterations underlie the pathogenesis of hepatic steatosis and are strongly associated with insulin resistance and type 2 diabetes. (1, 5, 6) Insulin-induced gene (Insig), an ER anchor protein, prevents ER-to-Golgi transport and activation of SREBPs by inhibiting the binding of SCAP to coat protein complex II proteins, which therefore exerts a negative feedback control system on lipogenesis in the liver. (7, 8) The expression of Insig proteins is reciprocally regulated by insulin in the liver: insulin strongly represses mRNA levels of Insig-2a, the predominant isoform of Insig-2 in the liver; but it induces Insig-1 expression. (7) Inhibition of Insig-2a has been proposed as the underlying mechanism of insulin-stimulated lipogenesis during refeeding, whereas the residual Insig-1 protein may be insufficient to block the processing and activation of SREBP-1c. (9) Although it is known that sterols prevent Insig-1 ubiquitination and degradation by displacing glycoprotein 78 from Insig-1, (10) the underlying mechanism of the hormonal regulation of Insig proteins during refeeding and its metabolic consequence in the feedback regulation of lipogenesis remain largely unknown. (7) CREB/ATF bZIP transcription factor (CREBZF), also known as Zhangfei, was identified as a basic region-leucine zipper (bZIP) transcription factor of the activating transcription factor (ATF)/cAMP response element-binding protein (CREB) gene family. (11) The ATF family proteins form a homodimer or heterodimer to bind a consensus cAMP response element, and a number of mammalian ATF or CREB proteins with diverse biological functions have been identified. (12) (13) (14) (15) Unlike most ATF/CREB family members, CREBZF does not bind DNA as a homodimer. (11, 16) Interestingly, CREBZF appears to function as a transcriptional cofactor for ATF4 (17) in the regulation of the cellular stress response. (16) Although CREBZF regulates cell growth by activating p53 activity, (18) it is largely unclear whether and how it regulates metabolism during physiology and nutrientoverload conditions.
Our recent studies demonstrate that SREBP activity and hepatic steatosis are inhibited by the key energy sensor adenosine monophosphate-activated protein kinase (AMPK) through phosphorylation in hepatocytes and in the liver of mice with type 2 diabetes. (19) Here, we investigated the mechanism of hormonal regulation of lipogenesis, and uncovered a link between insulin-Akt signaling and Insig-2a that contributes to fatty acid synthesis. Our data support the notion that insulin represses Insig-2a in the mammalian target of rapamycin complex I (mTORC1)-independent pathway. (9, 20) These in vivo and in vitro studies demonstrate that (1) insulin stimulates CREBZF expression in hepatocytes, (2) refeedinginduced transcriptional inhibition of Insig-2a is through CREBZF, (3) CREBZF inhibits Insig-2a by interacting
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with ATF4, and (4) CREBZF is essential for hepatic fatty acid synthesis during physiological and pathological conditions.
Materials and Methods

LIVER SPECIMENS FROM HUMANS
Livers were obtained from adult patients undergoing liver biopsy for the assessment of suspected nonalcoholic fatty liver or nonalcoholic steatohepatitis. (21) Normal control liver specimens were obtained for exclusion of liver malignancy during surgery between July 2010 and July 2013 in Zhongshan Hospital. None of the normal individuals underwent preoperative chemotherapy, and liver histology demonstrated absence of NAFLD, cirrhosis, and malignancy. Part of the liver specimens were preserved in formalin, and the other part of the same liver biopsy was placed on dry ice within a few minutes of removal from the liver and then stored in liquid nitrogen before use for molecular biology analysis. All subjects with the following conditions were excluded: known acute or chronic disease with the exception of obesity or type 2 diabetes mellitus, excessive alcohol consumption, or use of hepatic protectants or hepatotoxic agents in recent years. Patients gave written consent for their samples to be collected. Study of these specimens was approved by the Ethics Committee of Zhongshan Hospital, Fudan University, and was conducted in accordance with the 1975 Declaration of Helsinki.
ANIMAL MODEL AND DIETS
Liver-specific CREBZF knockout (CREBZF LKO) mice were generated by crossing floxed CREBZF mice containing the deleted open reading frame of CREBZF (Cyagen Biosciences, China) with albumin-cyclization recombination (Alb-Cre) recombinase transgenic mice (Model Animal Research Center of Nanjing University, China); wild-type (WT) littermates (Alb-Cre-negative, CREBZF flox/flox ) were used as the control. Male C57BL/6 mice at 8 weeks of age and Sprague-Dawley rats (200-250 g) were purchased from Shanghai Laboratory Animal Co. Ltd. (China). Mice were fed a high-fat, high-sucrose (HFHS) diet (D12327; Research Diets) for 16 weeks. All mice were housed under a 12:12-hour light/dark cycle at controlled temperature. All animal experimental protocols were approved by the Institutional Animal Care and Use Committee at the Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences.
PREDICTION OF METABOLIC REGULATORS
Gene expression profiles were analyzed using liver tissues of mice fed a chow diet or a high-fat diet for 16 weeks. (22) A set of differentially expressed genes that are enriched in the high-fat diet was identified (P < 0.05, t test). To identify candidate regulators of lipid metabolism, the TRED database (23) was used to retrieve known murine transcription factors. Additional transcription factors that have been validated in mice were obtained from a literature search. Only those transcription regulators that were differentially expressed and had high gene expression levels (average reads per kilobase million >1 in both the high-fat and chow groups) were used for further analysis.
STATISTICAL ANALYSIS
Data are expressed as mean 6 SEM. Statistical significance was evaluated using the unpaired two-tailed Student t test and among more than two groups by one-way analysis of variance. Differences were considered significant at P < 0.05.
Results
INSULIN STIMULATES EXPRESSION OF CREBZF TO PROMOTE DE NOVO LIPOGENESIS IN HEPATOCYTES
Nutrient overload-caused deregulation of lipid and glucose metabolism is critical for the development of hepatic steatosis, insulin resistance, and type 2 diabetes. To identify candidate metabolic regulators, we analyzed gene expression profiles of dietary models of murine obesity, which revealed a cluster of transcription factors enriched in the liver of high-fat diet-fed mice, including CREBZF (Fig. 1A) . To investigate whether CREBZF is responsive to hormonal signals, we analyzed the expression of CREBZF in hepatocytes using real-time PCR amplification. Interestingly, the mRNA levels of CREBZF were significantly increased by insulin in primary hepatocytes in a dose-dependent or time-dependent manner (Fig. 1B) . We next developed a rabbit polyclonal antibody against CREBZF and then confirmed its efficacy using cells transfected with complementary DNA encoding human CREBZF (Supporting Fig. S1A,B) . Insulin elicited a robust induction of the protein levels of CREBZF in a dose-dependent and time-dependent manner in primary hepatocytes as was evidenced by immunoblots using the antibody against CREBZF, which is consistent with a previous observation (Fig. 1C) . (24) Notably, phosphorylation of Akt was increased following insulin treatment. ) Male Sprague-Dawley rats were fed a normal diet, subjected to fasting, or fasted and then refed. Plasma insulin levels were assessed (H). Hepatic CREBZF expression was decreased by fasting and increased by refeeding in Sprague-Dawley rats (I). Livers were collected and analyzed by immunoblots. n 5 3-4. *P < 0.05 versus fed; # P < 0.05 versus fasted. Abbreviations: HFD, high-fat diet; HG, high glucose.
To test the metabolic function of CREBZF, adenoviruses encoding CREBZF or green fluorescent protein (GFP) as control were used to treat HepG2 cells under high-glucose plus insulin conditions, mimicking hyperglycemia and insulin resistance in vivo. (19) CREBZF treatment caused an induction of lipid accumulation in hepatocytes as evidenced by oil red O staining and triglyceride levels in a dose-dependent manner, which is correlated with an induction of protein levels of fatty acid synthase (FAS), a key downstream target of lipogenic transcription factor SREBP ( Fig. 1D-F) . (4) To test whether insulin-mediated stimulation of CREBZF expression is dependent on phosphoinositide 3-kinase (PI3K)-Akt signaling, protein kinase inhibitors were used to treat freshly isolated primary rat hepatocytes. Insulin stimulated an increased expression of CREBZF mRNA by 2-fold, whereas the induction was blocked by wortmannin (PI3K inhibitor) and Akti-1/2 (Akt inhibitor) (Fig. 1G) . Notably, the specificities of the kinase inhibitors were verified by immunoblotting analysis using the antibody against the phosphorylated forms of Akt.
To further explore whether CREBZF signaling is responsive to insulin in vivo, expression levels of CREBZF and FAS in the liver from fed, fasted, and refed rats were measured. Plasma insulin levels were significantly reduced following overnight fasting, which leads to a reduction of phosphorylation of Akt ( Fig.  1H,I ; Supporting Fig. S1C ). Strikingly, protein expression of hepatic CREBZF was repressed by nutrient deprivation and induced by nutrient availability, which is consistent with the previous observation showing increased expression of CREBZF by refeeding. (24) As expected, expression levels of FAS exhibited a similar pattern in response to the fasting and refeeding treatment, which is inversely correlated with the expression of Insig-2a. Together, these results suggest that CREBZF is a cellular factor that is induced by insulin-PI3K-Akt signaling and may play a role in the regulation of SREBP-dependent de novo lipogenesis in hepatocytes.
CREBZF LKO MICE ARE PROTECTED AGAINST HFHS DIET-INDUCED HEPATIC STEATOSIS
To explore the loss of function for CREBZF in vivo, CREBZF LKO mice were generated ( Fig.  2A,B) . The knockout efficiency was verified by immunoblotting analysis and real-time PCR (Fig. 2C,D) . CREBZF LKO mice and their WT littermates were placed on a chow diet or the HFHS diet for 16 weeks, and metabolic phenotypes of the mice were characterized. CREBZF LKO mice did not show significant metabolic changes compared with WT mice under the normal diet condition (Fig. 2E-G) . However, CREBZF deficiency in hepatocytes ameliorated hepatic steatosis as evidenced by histological analysis and measurements of chloroform/methanol-extracted lipids of the liver tissue. Moreover, compared with WT mice, plasma triglyceride and cholesterol levels were significantly decreased in CREBZF LKO mice fed the HFHS diet. These data strongly suggest that disrupting CREBZF function results in the improvement of hepatic steatosis in obesity.
Insig INHIBITION MEDIATES THE ABILITY OF CREBZF TO INDUCE LIPOGENESIS IN HEPATOCYTES
Next, the mechanism underlying the steatotic phenotypes of CREBZF-treated hepatocytes were investigated. We tested whether down-regulation of the lipogenic program in the liver is responsible for improved steatotic phenotypes in CREBZF LKO mice. Deletion of CREBZF caused a significant induction of Insig-2a and Insig-1 mRNA levels and reduction of the active nuclear form of SREBP-1 in the liver of mice fed the HFHS diet, which resulted in a reduction of SREBP-1's lipogenic targets and enzymes involved in fatty acid and triglyceride synthesis, including protein levels of FAS and mRNA levels of SREBP-1c, adenosine triphosphate citrate lyase, acetyl-coenzyme A carboxylase 1 (ACC1), FAS, stearoyl-coenzyme A desaturase 1, glycerol-3-phosphate acyltransferase, and diglyceride acyltransferases 1 and 2 ( Fig. 3A-D) . Notably, the expression levels of Insig are not obviously changed in chow-fed mice (Supporting Fig. S2 ). The inverse correlation between insulin-up-regulated CREBZF and insulindown-regulated Insig-2a (9) suggests that CREBZF may repress Insig activity to allow SREBP-1c processing and activation, (7) which is consistent with the observation that CREBZF functions as a repressor of gene transcription. (25) These data suggest that hepatic deletion of CREBZF ameliorates HFHS diet-induced hepatic steatosis, possibly through augmentation of Insig-mediated repression of hepatic lipogenesis.
Insig-2a IS INHIBITED BY CREBZF-ATF4 HETERODIMER, LEADING TO ENHANCED DE NOVO LIPOGENESIS IN HEPATOCYTES
We next delineated the mechanism of CREBZFmediated inhibition of Insig in vitro. Luciferase-based reporter assays were performed. The activity of mouse Insig-2a promoter-driven reporter was significantly repressed by treatment with FLAG-tagged CREBZF, suggesting that CREBZF represses transcription of Insig-2a (Fig. 4A) . Given that CREBZF does not bind DNA by itself (11) and acts as a transcriptional cofactor of another bZIP transcription factor, ATF4, in the regulation of cellular stress response, (16, 17) we hypothesized that ATF4 may be required for CREBZF-mediated inhibition of Insig-2a. First, we found that the inhibition of CREBZF on Insig-2a was enhanced by cotreatment with ATF4 ( Fig. 4A ; Supporting Fig. S3A ). We next elucidated a causal relationship between ATF4 and CREBZF-mediated inhibition of Insig-2a and augmentation of triglyceride levels in hepatocytes using adenoviruses encoding short hairpin RNAs (shRNAs) targeting mouse ATF4 (AdshATF4). The specificity of ATF4 knockdown was confirmed by measuring ATF4 protein levels in primary mouse hepatocytes under treatment with the ER stress inducer tunicamycin or thapsigargin, whereas no obvious changes in glucose-regulated protein 78 expression were evidenced ( Fig. 4B,C; Supporting Fig.  S3B ). Strikingly, effects of CREBZF on Insig-2a inhibition, SREBP-1c induction, and triglyceride accumulation were diminished by Ad-shATF4 in hepatocytes, which is consistent with observations that ATF4 knockout mice are protected against diet-induced hepatic steatosis. (26) Taken together, these results suggest that CREBZF may inhibit Insig-2a to enhance lipogenesis through ATF4 in a cell autonomous manner.
To study whether CREBZF inhibits Inisig-2a activity by the formation of a heterodimer with ATF4, glutathione S-transferase (GST) pull-down and immunoblotting analyses were performed. FLAGtagged ATF4 was present in the complex with GSTtagged CREBZF, and endogenous CREBZF was present in reciprocal GST pull-down analysis using GST-tagged ATF4 (Fig. 4D) . Moreover, endogenous ATF4 was also coimmunoprecipitated in the complex with overexpressed CREBZF (Fig. 4E) . These data indicate that CREBZF indeed associates with ATF4. To further map the region of CREBZF that is responsible for binding to ATF4, GST pull-down analysis was performed using a series of deletion mutants of CREBZF. The C-terminal region (amino acids 127-272) containing the bZIP domain was sufficient for CREBZF to bind ATF4, whereas the N-terminal region (amino acids 1-126) disrupted the interaction ( Fig. 4F; Supporting Fig. S3C ). Consistently, CREBZF mutants with disruption of the bZIP domain, such as CREBZF (186-272) and DbZIP, Cells were treated with adenoviruses encoding shRNAs targeting ATF4 (shATF4) or negative control, followed by treatment without or with tunicamycin (2 lg/mL) or thapsigargin (300 nM) in serum-free medium overnight. n 5 4, *P < 0.05 versus GFP and negative control. (C) ATF4 knockdown attenuates CREBZF-induced triglyceride storage in primary hepatocytes exposed to high glucose plus insulin. n 5 6. *P < 0.05 versus GFP; # P < 0.05 versus GFP, glucose, and insulin; $ P < 0.05 versus CREBZF, glucose, and insulin. (D) ATF4 physically associates with endogenous CREBZF in HEK293 cells. GST, GST-CREBZF, or FLAG-ATF4 was transiently transfected into HEK293 cells and purified with GSH Sepharose beads. Precipitates and lysates were individually immunoblotted with antibodies against ATF4 or GST. (E) Endogenous ATF4 interacts with FLAG-tagged CREBZF in HEK293 cells. (F) Mapping of the ATF4-binding region in CREBZF in HEK293 cells. FLAG-tagged CREBZF and its truncate mutants were cotransfected with GST-tagged ATF4 in cells as indicated, followed by GST pull-down analysis. (G) The occupancy of endogenous ATF4 on the Insig-2a promoter is abrogated by CREBZF deficiency in HFHS diet-fed mouse livers. In vivo quantitative chromatin immunoprecipitation assays were performed using ATF4 antibody or control antibody against IgG. n 5 5-8. *P < 0.05 versus WT mice with IgG immunoprecipitation in the specific C/EBP-ATF composite site; # P < 0.05 versus WT mice with ATF4 immunoprecipitation in the specific C/EBP-ATF composite site. Abbreviations: GRP78, glucose-regulated protein 78; HG, high glucose; IB, immunoblot; IP, immunoprecipitate; NC, negative control. failed to interact with ATF4. These results demonstrate that the bZIP domain of CREBZF is required for the interaction with ATF4.
Insig-2a promoter mapping analysis was performed to identify a potential DNA element responsible for the CREBZF/ATF4 complex. The full-length mouse Insig-2a promoter (22181/185) and a series of 5 0 deletion Insig-2a promoter vectors were cloned and then inserted into a pGL3-Basic reporter vector. Insig-2a (22181/185) promoter activity showed a reduction in HepG2 cells in response to CREBZF treatment (Supporting Fig. S3D ). Progressive 5 0 flanking deletion reporters, including (21539/185), (21000/185), (2597/185), and (2300/185), remained a profound response to CREBZF, in a similar manner to that of full-length Insig-2a promoter. Strikingly, fine mapping analysis within the -300 region showed that the deletion reporter Insig-2a (250/185) and (225/185) resulted in a decrease of basal Insig-2a activity and led to elimination of almost all of the inhibitory effects of CREBZF, suggesting that the regulatory region located between -100 and -25 is likely responsible for CREBZF-inhibited Insig2a transcription. Furthermore, two evolutionarily conserved ATF4 binding sites, the CCAAT/enhancer binding protein (C/EBP)-ATF composite site, (27, 28) were identified in this promoter region (Supporting Fig. S3E ).
To further define whether hepatic CREBZF is relevant to ATF4 in regulating Insig-2a in vivo, FIG. 5 . Hepatic inhibition of Insig restores the expression of SREBP-1 and its target lipogenic enzymes in CREBZF-deficient hepatocytes exposed to high glucose plus insulin. After a 24-hour period of transfection with Ad-sh-negative control, Ad-shInsig-1, sinegative control, or siInsig-2a, CREBZF 1/1 or CREBZF -/-mouse primary hepatocytes were incubated in serum-free Dulbecco's modified Eagle's medium containing 5.5 mM glucose for 24 hours and then treated with high glucose plus insulin for 24 hours. (A,B) Real-time PCR (A) and immunoblotting (B) analyses were performed. n 5 5-6, *P < 0.05 versus CREBZF 1/1 treated with sh-negative control and si-negative control; # P < 0.05 versus CREBZF 1/1 treated with sh-negative control, si-negative control, glucose, and insulin; & P < 0.05 versus CREBZF -/-treated with sh-negative control and si-negative control. Abbreviations: NC, negative control; SCD1, stearoyl coenzyme A desaturase 1.
chromatin immunoprecipitation was performed in livers of CREBZF LKO mice fed the HFHS diet. ATF4 was recruited and bound to the C/EBP-ATF composite site on the Insig-2a promoter in WT mouse livers as detected using primers extending from -117 to 118 but not with primers that amplify control distant regions from -4505 to -4378 (Fig. 4G) . Strikingly, the occupancy of ATF4 to the Insig-2a promoter was abrogated in livers of CREBZF LKO mice. The data indicate that CREBZF is required for ATF4 to bind Insig-2a promoter and may mediate the inhibitory effects on Insig-2a activity. Taken together, these data suggest that CREBZF associates with ATF4 to inhibit Insig-2a activity in a hepatocyteautonomous manner.
To demonstrate direct control of lipogenesis by the CREBZF-Insig pathway, knockdown of both Insig-1 and Insig-2 using Ad-shInsig-1 or small interfering RNA (siInsig-2) was performed in primary hepatocytes under high-glucose plus insulin-treated conditions. (19) shInsig-1-235 and siInsig-2-944, which produced the greatest knockdown efficiency, were chosen for the following experiments (Supporting Fig. S4A ). Compared with CREBZF 1/1 cells, CREBZF deficiency caused a 3-fold reduction in lipogenic gene expression in hepatocytes exposed to high glucose plus insulin, including SREBP-1c, ACC1, and FAS, which is consistent with the observation that CREBZF LKO mice are protected against hepatic steatosis in Fig. 2 (Fig. 5A,B;  Supporting Fig. S4B) . Strikingly, the expression levels of these lipogenic genes in CREBZF -/-hepatocytes exposed to high glucose plus insulin were restored by hepatic inhibition of both Insig-1 and Insig-2. Consistently, compared with CREBZF 1/1 cells, double knockdown of Insig-1 and Insig-2 did not cause obvious effects. Notably, elimination of either Insig-1 or Insig-2a alone does not rescue the reduction of lipogenic genes expression in CREBZF -/-cells (Supporting Fig. S4C ), which is consistent with the redundant functions of the two Insig genes. (29) Notably, knockdown efficiency of Insig was evidenced. Taken together, these data strongly indicate that CREBZF inhibits both Insig-2a and Insig-1 to increase SREBP1c activity and promote lipogenesis.
CREBZF IS NECESSARY FOR INSULIN-INDUCED LIPOGENESIS IN MICE
To study the relative contribution of CREBZF to insulin-induced lipogenesis, a fasting and refeeding assay was performed. Expression levels of lipogenic enzyme FAS were increased by refeeding, and the induction was attenuated in the liver of CREBZF LKO mice (Fig. 6A-C) . Moreover, the mRNA levels of Insig-2a and Insig-1 were increased, whereas SREBP-1c's downstream targets such as SREBP-1c, ACC1, and FAS were reduced, in CREBZF LKO mice in response to refeeding. These data suggest that insulin promotes a lipogenic program in a CREBZF-dependent manner. To further test this hypothesis, CREBZF LKO or WT mice were subjected to insulin deficiency by administration of streptozotocin (STZ), a toxin that destroys insulinsecreting beta cells of the pancreas, (30) followed by treatment with or without insulin. Consistently, CREBZF deficiency caused induction of Insig-2a and Insig-1 and reduction of protein levels of FAS and mRNA levels of SREBP-1c, ACC1, and FAS under STZ and insulin treatment (Fig. 6D-F) . Notably, insulin levels of the mice under fasting and refeeding or STZ1insulin treatment were measured (Supporting Fig. S5 ). Taken together, these data strongly suggest that CREBZF is required by insulin to stimulate de novo lipogenesis in mice.
ELEVATION OF CREBZF IN THE STEATOSIS LIVER OF MICE AND HUMANS
We next investigated the expression levels of hepatic CREBZF in mice and humans with hepatic steatosis. Compared with chow-fed mice and lean controls, mRNA levels of CREBZF in the liver were significantly higher in HFHS diet-induced obese mice or genetically obese ob/ob mice caused by leptin deficiency, suggesting a positive correlation of CREBZF activation in the development of hepatic steatosis (Fig. 7A,B) . To gain insight into the clinical relevance of CREBZF, the steatosis and normal control liver specimen of humans were immunostained using antibody against CREBZF. Compared with minimal immunostaining of liver sections using nonimmunoglobulin G (IgG), the intense staining for CREBZF was primarily localized in the nucleus of hepatocytes, which is consistent with its role in the transcriptional regulation of Insig-2a (Fig. 7C) . Strikingly, immunoreactivity for CREBZF was markedly induced in the steatosis liver of humans compared with that of normal controls. Furthermore, real-time PCR analysis was performed. mRNA levels of CREBZF were significantly increased in the steatotic liver compared with that of the control group, which is associated with a reduction of Insig-2 and Insig-1 activity (Fig. 7D) . These data provide clinical relevance of CREBZF in regulating lipogenic enzyme expression and fatty acid synthesis.
We further explored the association of CREBZF with human hyperlipidemia. Out of 10 singlenucleotide polymorphisms with minor allele frequencies >0.01 in the 1000 Genomes phase 3 population of Han Chinese in Beijng (CHB) (data release 2, May 2013, on National Center for Biotechnology Information GRCh37 assembly), located in the encoding and flanking regions of the CREBZF locus, we genotyped 5 tagging singlenucleotide polymorphisms (r 2 threshold 5 0:8) in the Nutrition and Health of Aging Population in China study (Fig. 7E,F ; Supporting Table S1 ). We found that the minor allele T of rs3824956 and the minor allele G of rs7119617 are significantly correlated with higher levels of high-density lipoprotein cholesterol. Taken together, our results suggest that CREBZF may be linked to the pathogenesis of hepatic steatosis and dyslipidemia in rodents and humans. 
Discussion
The current study reveals an insulin-induced protein, called CREBZF, that modulates insulin responsiveness of a subset of lipogenic genes through inhibition of Insig. CREBZF acts as a bona fide upstream regulator of Insig for hormonal modulation of hepatic fatty acid metabolism through PI3K-Akt signaling. CREBZF-dependent inhibition of Insig may represent a molecular mechanism by which extracellular hormonal cues are transduced into the cell and then regulate Insig-mediated feedback regulation of lipogenesis, which may contribute to hepatic steatosis, dyslipidemia, and insulin resistance.
CREBZF ACTS AS AN ESSENTIAL COMPONENT IN THE INSULIN-REGULATED PATHWAY FOR HEPATIC LIPOGENESIS
It was not known how Insig-2a decreases during refeeding. (7) Our data suggest that insulin-CREBZF signaling directly inhibits the transcription of Insig-2a during refeeding, whereas recent observations reported glucocorticoid-SETDB2-mediated activation of Insig2a during fasting. (31) Our findings further uncover important mechanisms of the dynamic regulation of Insig-2a during fasting to refeeding. Moreover, the mechanism of insulin-Akt-mediated and mTORC1-independent repression of Insig-2a and activation of SREBP-1c has not been identified. (20) Our results suggest that CREBZF may play an essential role in this process, which couples insulin-PI3K-Akt signaling to de novo lipogenesis by inhibiting Insig-2a. However, the detailed mechanism that mediates activation of CREBZF in response to insulin requires further investigation. Notably, insulin was shown to regulate Insig mRNA turnover, (32) suggesting a posttranscriptional mechanism to regulate lipogenesis.
Aberrant lipogenesis and excessive fatty acid synthesis in the liver are tightly associated with hepatic steatosis, (5) which is consistent with our findings that activation of CREBZF stimulates lipogenesis and contributes to hepatic steatosis in hepatocytes. Moreover, expression levels of CREBZF are increased in livers of diet-induced insulin resistance or genetically obese ob/ob mice and humans with hepatic steatosis. Hyperactivation of CREBZF may underscore the potential role of CREBZF in the development of sustained lipogenesis in the liver under selective insulin resistance conditions, in which insulin retains its ability to stimulate fatty acid synthesis, whereas it loses its ability to inhibit gluconeogenesis. These results establish that CREBZF acts as an essential component in the insulin-regulated pathway for hepatic lipogenesis and controls lipid metabolism, which may help us to understand the paradox of selective insulin resistance in the liver of diabetes.
CREBZF SERVES AS A NEGATIVE REGULATOR OF Insig-2a DURING REFEEDING
One of the major findings of the present study is the characterization of CREBZF and ATF4 as critical components for Insig-2a transcription, which synergistically regulates liver lipid metabolism in response to refeeding. CREBZF deficiency diminished the binding of ATF4 to the C/EBP-ATF composite site-containing region of the Insig-2a promoter in the liver of HFHS diet-fed mice, suggesting that Insig-2a may be a direct target of the CREBZF-ATF4 complex. These results indicate that both CREBZF and ATF4 physically interact and localize in the nucleus, (11, 25) where they are consequently bound to the C/EBP-ATF composite site of the Insig-2a promoter, thus repressing Insig-2a transcription in a hepatocyte-dependent manner. Our findings illuminate a mechanism by which CREBZF blocks the feedback regulation of the SREBP processing system by inhibiting Insig-2a. During refeeding, insulin-induced activation of CREBZF inhibits Insig-2a expression in hepatocytes, allowing SREBP-1 to be processed and activation of fatty acid synthesis. Moreover, CREBZF activation regulates lipid metabolism at least in part through the down-regulation of Insig. Inhibition of Insig-1 and Insig-2 restores the expression of SREBP-1 and its target lipogenic enzymes in CREBZF -/-hepatocytes, supporting the essential role of Insig in mediating lipogenic effects of CREBZF.
Moreover, regulation of SREBP is controlled by transcriptional and posttranscriptional levels. The posttranscriptional regulation is mainly controlled by Insig and SCAP controlled ER-to-Golgi transport and processing of SREBP, whereas the transcriptional regulation is controlled by SREBP-mediated feed-forward transcription of its own gene through an SRE and liver X receptor (LXR)-mediated transcription through an LXR response element. (4) Our results indicate that CREBZF strongly promotes SREBP-1c activity and fatty acid synthesis by inhibiting Insig. Interestingly, adenovirus-mediated overexpression of CREBZF was shown to inhibit LXR agonist T0901317-induced lipogenic gene expression. (33) CREBZF-mediated activation of SREBP-1c and repression of LXR may provide a means for the cell to achieve an appropriate amount of fatty acid and therefore maintain hepatic lipid homeostasis in response to nutrient availability. Together, the hepatocyte-specific CREBZF-ATF4-Insig-2a signaling may provide insight into the molecular basis for the role of the insulin-CREBZF signaling pathway in the control of fatty acid metabolism.
DELETION OF CREBZF IN THE LIVER IMPROVES ABERRANT LIPID METABOLISM UNDER INSULIN-RESISTANT CONDITIONS
Several lines of evidence support a critical role of CREBZF in regulating lipid metabolism during physiological conditions or in developing hepatic steatosis in response to nutrient-overload conditions (Supporting Fig. S6 ). First, hepatic CREBZF deficiency causes a potent reduction of lipogenic gene expression in the liver of mice in response to refeeding or under treatment with STZ and insulin. Second, compared with WT mice, CREBZF LKO mice show a profound reduction of lipogenic gene expression and protection against HFHS diet-caused hepatic steatosis, which is in contrast to the steatotic phenotypes of liver-specific Insig-1 and whole-body Insig-2 double knockout mice (L-Insig-1, Insig-2 -/-) (29) with hyperactivation of lipogenic genes as well as the synthesis of fatty acid. Moreover, our results support the hypothesis that in the insulin-resistant state hyperinsulinemia may contribute to activation of CREBZF and excessive lipid accumulation in the liver and plasma, which may further exacerbate hepatic insulin resistance and increase the risk of developing atherosclerosis-associated metabolic syndrome. This hypothesis is supported by the evidence that plasma levels of triglyceride and cholesterol are reduced in CREBZF LKO mice fed the HFHS diet, and by the finding that hepatic insulin resistance has a critical role in the development of dyslipidemia and atherosclerosis. (34) In summary, the present study has identified a central role of the insulin-CREBZF axis that regulates de novo lipogenesis through Insig. The identification of Insig-2a as a direct target of CREBZF further solidifies the role of CREBZF as an insulin sensor that functions to regulate fatty acid synthesis in hepatocytes. These findings conceptually advance our understanding of the hormonal regulation of hepatic lipogenesis through the ATF/CREB family transcription factor. These findings may have therapeutic implications for hepatic steatosis, hyperlipidemia, and insulin resistance.
